Article about BioMedomics’s COVID-19 IgM/IgG Rapid Antibody Test Awarded as Top Cited Paper in Journal of Medical Virology!

An article about BioMedomics’s COVID-19 IgM/IgG Rapid Antibody Test that several employees of BioMedomics, Inc., worked on has been awarded as one of the top cited papers 2019-2020 by the Journal of Medical Virology!

The Journal of Medical Virology is a peer-reviewed medical journal covering fundamental and applied research in regard to viruses that effect humans.

Congratulations to our team members for their contribution towards educating the public on the importance and effectiveness of COVID-19 antibody tests! To read the article, click here.

 

 

SARS-CoV-2 Antigen Test Kit (LFIA) Granted CE Certification!

Last year, BioMedomics was one of the world’s first companies to launch the CE-marked COVID-19 Combined IgM/IgG Rapid Antibody test for qualitative, differential detection of IgM and IgG antibodies to SARS-CoV-2 in human serum, plasma, or whole blood samples in under 15 minutes. The ease of use of the test played a key role in combatting the COVID-19 pandemic and the test is now expected to play a larger role in detecting neutralizing antibodies for assessing the effectiveness of vaccines.

The all new SARS-CoV-2 Antigen Test Kit (LFIA) detects SARS-CoV-2 in nasopharyngeal secretions directly collected from individuals who are suspected of COVID-19 by their healthcare provider. It has a test time of 15 minutes in lower viral presence however in high viral load presence, the positive line can appear as quickly as 3 minutes. The test is easy to use and can be used at the point of care, public locations such as airports, schools and even the neighborhoods and communities in surveillance, contact tracing and initiation of treatment.

The use of SARS-CoV-2 Rapid Antigen Test Kit (LFIA) along with the IgM/IgM Rapid Antibody test offers a complete solution in the diagnosis of COVID-19. For more information, please contact sales@biomedomics.com or visit https://www.biomedomics.com/products/infectious-disease/sars-cov-2-antigen-test-kit-lfia/.

 

*Export only. Not for sale in USA.

BioMedomics, Inc.’s ISO 13485 Certification Granted Expansion

BioMedomics, Inc. is proud to announce its ISO 13485:2016 certificate has expanded in scope to include the design, development and manufacturing of COVID-19 rapid tests.  The certification is accredited by BSI Group America.

The certification of compliance with ISO 13485:2016 recognizes that the policies, practices and procedures of our company ensure consistent quality in the product and services we provide our clients. With this certification, our clients can be confident that BioMedomics, Inc. is dedicated to maintaining the highest efficiency and responsiveness in achieving our ultimate goal – guaranteed client satisfaction.

BioMedomics, Inc. is certified as meeting the requirements of ISO 13485:2016 for the following activities:

The design, development and manufacture of in-vitro diagnostic medical devices used in the detection of hemoglobin disorders and/or adaptive immune responses including laboratory and point-of-care in-vitro diagnostic medical devices.

To maintain our certification, we will perform audits to ensure compliance and to assess initiatives for continued improvement. Our clients can be confident that BioMedomics, Inc. will continue to provide the high-quality products and services they have come to expect well into the future.

We believe that our decision to expand our ISO certification to include our COVID-19 product line is a proactive one that not only anticipates the demands of our clients, but also demonstrates our commitment to providing quality services to all our clients.

COVID-19 IgM/IgG Rapid Test Approved by INVIMA in Colombia!

We are excited to announce that the National Institute for Food and Drug Surveillance (INVIMA) has given BioMedomics, Inc. authorization to sell and distribute our COVID-19 IgM/IgG Rapid Test in Colombia!

We have partnered with Piso Pélvico-GILMEDICA S.A. to assist with distributing our product to customers. For sales requests in Colombia, please contact Mr. Julián Potes by email (julian.potes@gilmedica.com) or phone (+57 318 827 49 94).

BioMedomics’s COVID-19 IgM/IgG Rapid Test is one of the first and most accurate COVID-19 antibody rapid tests on the market, winning over competitor testing methods with:

  • Fastest test result of 10-15 minutes
  • Highest combined sensitivity/specificity (100%/~99%)
  • Intuitive visual interpretation
  • No special equipment needed

For information or questions about our COVID-19 IgM/IgG Rapid Test, please email info@biomedomics.com

To receive a quote and place an order, please email sales@biomedomics.com

*Not available for sale within the USA.